Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Stock Has Consensus Price Target of $38.33 According to Analysts

Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) have earned a consensus rating of “Buy” from the five research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $38.33.

Several research firms recently commented on ELOX. Leerink Partners set a $32.00 price target on Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, September 18th. Lucid Cap Mkts upgraded Eloxx Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 20th. Lifesci Capital initiated coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating and issued a $43.00 target price on shares of Eloxx Pharmaceuticals in a research report on Monday, August 24th. Finally, Weiss Ratings assumed coverage on Eloxx Pharmaceuticals in a research note on Friday, August 14th. They set a “sell (d)” rating for the company.

Eloxx Pharmaceuticals Trading Up 3.6%

Eloxx Pharmaceuticals stock opened at $16.00 on Friday. Eloxx Pharmaceuticals has a 1 year low of $8.20 and a 1 year high of $23.40. The firm has a 50 day moving average of $16.28. The stock has a market capitalization of $64.64 million, a P/E ratio of -10.39 and a beta of -1,862.26.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions.

Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations.